U.S. Diversified Financial Stock News

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Unicycive Therapeutics, Inc. ( NASDAQ:UNCY ) is possibly approaching a major achievement in its business, so we would...

Key Insights Significantly high institutional ownership implies BioAge Labs' stock price is sensitive to their trading...

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

TriMas Corporation's ( NASDAQ:TRS ) price-to-earnings (or "P/E") ratio of 32.3x might make it look like a strong sell...

The Silicon Motion Technology Corporation ( NASDAQ:SIMO ) share price has done very well over the last month, posting...

While it may not be enough for some shareholders, we think it is good to see the Tucows Inc. ( NASDAQ:TCX ) share price...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Many The Andersons, Inc. ( NASDAQ:ANDE ) insiders ditched their stock over the past year, which may be of interest to...

Some Dycom Industries, Inc. ( NYSE:DY ) shareholders may be a little concerned to see that the Independent Director...

Key Insights Given the large stake in the stock by institutions, Oil-Dri Corporation of America's stock price might be...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Insiders who bought US$361.4k worth of Caleres, Inc. ( NYSE:CAL ) stock in the last year have seen some of their losses...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...

Key Insights Given the large stake in the stock by institutions, Heron Therapeutics' stock price might be vulnerable to...

Recent commentary on TopBuild (BLD) spotlights how its installer distributor model is benefiting from the current construction boom, along with consistent earnings beats and shares trading near all time highs, which is drawing more investor attention. See our latest analysis for TopBuild. At a share price of $465.73, TopBuild has had a 6.84% 1 month share price return and a 47.76% 1 year total shareholder return. This suggests momentum has been building as investors weigh the construction...

Valens Semiconductor (VLN) is back on investor radar after securing a fourth MIPI A PHY design win in China and launching a production ready A PHY enabled e mirror with Sakae Riken Kogyo. See our latest analysis for Valens Semiconductor. The recent A PHY design wins and e mirror launch sit against a sharp short term rebound, with a 30 day share price return of 55.97% and year to date share price return of 58.97%. This contrasts with a 1 year total shareholder return decline of 19.48% and a 3...

LENZ Therapeutics and Lunatus Marketing & Consulting FZCO recently announced an exclusive agreement for Lunatus to register and commercialize VIZZ, an FDA-approved aceclidine-based eye drop for presbyopia, across multiple Middle East markets including the UAE, Saudi Arabia and Qatar. The deal builds on VIZZ’s early U.S. launch, where the product generated about US$1.6 million in Q4 2025 revenue from over 20,000 prescriptions and broad uptake by eye care professionals. We’ll explore how early...

JPMorgan’s new coverage of TIC Solutions (TIC), highlighting its technical depth and acquisition integrations, has put the stock in focus as investors weigh cross-selling prospects and planned cost synergies against a recent earnings miss. See our latest analysis for TIC Solutions. The JPMorgan coverage has arrived after a choppy stretch for TIC Solutions, with a 90 day share price return of a 10.2% decline but a year to date share price return of 15.77%. The 1 year total shareholder return...

Recently, Citizens began covering Tri Pointe Homes with a "Market Outperform" rating, coinciding with a fall in average two-year fixed mortgage rates below 4% and management comments about encouraging early demand signs for 2025 despite a weaker backlog. This combination of a new supportive analyst view, easing financing costs for buyers and cautious management optimism has sharpened investor attention on how Tri Pointe might perform if housing demand continues to stabilize. Next, we’ll...

Aquestive Therapeutics recently disclosed that the FDA has identified unspecified deficiencies in the New Drug Application for its orally delivered epinephrine film Anaphylm, pausing labeling discussions and potentially affecting the timing of any approval decision ahead of the scheduled 31 January 2026 PDUFA date. At the same time, the company is pressing ahead with plans to seek approvals for Anaphylm in Canada, Europe, and the UK in 2026, signaling an effort to build a global,...